Trials / No Longer Available
No Longer AvailableNCT00493532
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 80 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ibandronate [Bonviva/Boniva] | 3mg iv every 3 months |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2007-06-28
- Last updated
- 2016-11-02
Locations
14 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00493532. Inclusion in this directory is not an endorsement.